Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 16;14:719–728. doi: 10.2147/DMSO.S288482

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Ji et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

miR-7a inhibits the viability and invasion capacity of Endothelial cells and Retinal pericytes. (A and B) Western blot analysis for expression of IRs-2 in Endothelial cells and Retinal pericytes co-transfected with miR-7a mimic, control, miR-7a inhibitor or its control. (C) Relative expression of proteins in endothelial cells and Retinal pericytes. (D) Number of invading Endothelial cells and Retinal pericytes. (E) Results of cell viability done by MTT assay for Endothelial cells and Retinal pericytes. (F) Viability of retinal pericytes co-transfected with miR-7a mimic, control, miR-7a inhibitor or its control. Results are presented as the mean ± standard deviation (n=3). *P<0.05 compared to mimic control, ^@P<0.05 compared to inhibitor control.